MPS II in females: molecular basis of two different cases

Editor—Hunter disease or mucopolysaccharidosis type II (MPS II, MIM 309900) is an X linked recessive disease resulting from deficiency of the lysosomal enzyme iduronate-2-sulphatase (IDS, E.C.3.1.6.13).1 The IDS cDNA has been isolated2 and the genomic region containing the IDS gene and pseudogene has been completely sequenced.3 Phenotypic expression of X linked disorders in females may be the result of an X chromosome anomaly or homozygosity for the mutated gene, but is most frequently the result of skewed X chromosome inactivation. We describe two affected girls, case 1 and case 2, with a mild and a severe form of MPS II, respectively. Both have a normal karyotype but increased dermatan sulphate and heparan sulphate excretion in urine, a marked deficiency of IDS activity, and normal α-L-iduronidase, β-D-glucuronidase, and arylsulphatase A activities in leucocytes and cultured skin fibroblasts ruling out MPS I, MPS VII, and multiple sulphatase deficiency. Molecular studies showed that case 1 is the first case of female MPS II with two mutated IDS genes and that case 2 has a de novo gene rearrangement on the paternal allele (a 3254 bp deletion from intron 7 to intron 8 with an insertion of 20 bp) associated with skewed X inactivation of the normal maternal X chromosome.

Case 1 was born into a French gypsy family. At 11 years of age, she presented with hepatomegaly and growth retardation, but had no dysmorphic features, no multiplex dysostosis, no corneal clouding, no cardiovascular disease, no mental retardation, but had no dysmorphic features, no multiplex dysostosis, no corneal clouding, no cardiovascular disease, no mental retardation, in agreement with the result of skewed X chromosome inactivation. We describe two affected girls, case 1 and case 2, with a mild and severe form of MPS II, respectively. Both have a normal karyotype but increased dermatan sulphate and heparan sulphate excretion in urine, a marked deficiency of IDS activity, and normal α-L-iduronidase, β-D-glucuronidase, and arylsulphatase A activities in leucocytes and cultured skin fibroblasts ruling out MPS I, MPS VII, and multiple sulphatase deficiency. Molecular studies showed that case 1 is the first case of female MPS II with two mutated IDS genes and that case 2 has a de novo gene rearrangement on the paternal allele (a 3254 bp deletion from intron 7 to intron 8 with an insertion of 20 bp) associated with skewed X inactivation of the normal maternal X chromosome.

Table 1 Primers or oligoprobes (IDS) used for PCR, sequencing, mutagenesis, or ASO hybridisation

<table>
<thead>
<tr>
<th>Primers Position (L35485)</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR/sequencing</td>
<td></td>
</tr>
<tr>
<td>I1.1</td>
<td>nt 1805-1824 5'-TCCAGCTTGGGCTCTTAG</td>
</tr>
<tr>
<td>Exl.3'</td>
<td>nt 2087-2066 5'-CTCAATGCAAGAAAGCAACA</td>
</tr>
<tr>
<td>Pro1</td>
<td>nt 83-104 5'-GGGCTTTGTTATAGATTGATTC</td>
</tr>
<tr>
<td>Ex3.3'</td>
<td>nt 2940-2919 5'-AATGCTGGATTCAGACACCAC</td>
</tr>
<tr>
<td>DB5</td>
<td>nt 19094-19114 5'-GGTGAGCTTACAGATGCCAT</td>
</tr>
<tr>
<td>DB6</td>
<td>nt 19267-19247 5'-CTGGCTCCATCAACTGGTAGG</td>
</tr>
<tr>
<td>delS</td>
<td>nt 20075-20098 5'-GCAATTCCAGGGACAGTGTAAC</td>
</tr>
<tr>
<td>del AS</td>
<td>nt 20874-20861 5'-CAAGCTCTTTGAGTACCTGACAG</td>
</tr>
<tr>
<td>Mutagenesis</td>
<td></td>
</tr>
<tr>
<td>mut-L41P</td>
<td>nt 1927-1911 5'-CGATGATGAGAAGAGACC</td>
</tr>
<tr>
<td>mut-XhoI</td>
<td>nt 1927-1911 5'-CGATGATGAGAAGAGACC</td>
</tr>
<tr>
<td>ASO</td>
<td></td>
</tr>
<tr>
<td>L41L</td>
<td>nt 1927-1911 5'-CGATGATGAGAAGAGACC</td>
</tr>
<tr>
<td>L41P</td>
<td>nt 1927-1911 5'-CGATGATGAGAAGAGACC</td>
</tr>
<tr>
<td>ASO: the mutated base is in bold.</td>
<td></td>
</tr>
</tbody>
</table>

No sample from the father was available. Experiments were conducted for checking a deletion on the paternal allele. Southern blotting of the proband’s DNA did not show any gene rearrangement (results not shown). Fluorescence in situ hybridisation was performed on mitotic metaphase chromosomes from her lymphoblastoid cells (Lβ) with two probes (see legend to fig 1). Two green spots can be seen at the IDS gene locus (fig 1), excluding an IDS gene deletion on the paternal X chromosome. The proband’s father should carry the previously undescribed L41P mutation and is probably mildly affected. In our experience, one very mildly affected grandfather was found to be a carrier of a mild mutation and remained undiagnosed until a family study (unpublished data). The high rate of consanguinity in the gypsy community could explain why both parents are carriers of this rare mutation. If the father is not a carrier, this homozygosity could be explained either by partial maternal disomy or by a de novo event. This latter hypothesis is unlikely as it would create the same rare mutation on the paternal X chromosome.

Normal (L41L) and mutated (L41P) cDNA was transfected into different cells, normal skin fibroblasts, Lβ from an MPS II patient with a total deletion of the IDS gene (Lβ del),4 and COS-7 cells. Mutant IDS L41P cDNA in pTK vector (pTK IDS) and pREP4 vector (pREP IDS) were generated as previously described.5 The sequences of the oligonucleotides (mut-L41P and mut-XhoI) are indicated in table 1 and the mutated cDNA was sequenced. Lβ del and normal skin fibroblasts were transfected by electroporation with pREP IDS and pTK IDS respectively, as previously described.5 COS cells were transfected with pTK IDS using FuGENE™ 6 (Roche). Wild type IDS cDNA and L41P mutant cDNA were transiently expressed in COS cells and normal human skin fibroblasts and stably expressed in Lβ del.6

The processing of the wild type IDS protein is identical in all these cells.7-4 After a three hour pulse, COS cells, normal fibroblasts, and Lβ del transfected with L41P mutant cDNA produced only the 76 kDa precursor, and after a 24 hour chase, no 55 kDa lysosomal mature form was produced in any of the different cell types expressing L41P, while the 76 kDa polypeptide was degraded (fig 2, table 2). Expression study of the mutant cDNA (L41P) in different cell types does not explain the mild phenotype in case 1, as no mature lysosomal IDS could be visualised (fig 2). L41P affects a highly conserved amino acid in seven of
nine sulphatases" and the mutation prevents the proper folding of IDS in an early step of the processing (no 90 kDa form is produced).

No IDS activity was observed in L41P transfected Lß del. An increase in IDS activity was observed in COS cells and normal fibroblasts transfected by L41P, 3.8% and 28.8% of the IDS activity produced by the wild type cDNA, respectively (table 2). This residual activity of the L41P mutation expressed in cells with a basal IDS activity (COS and normal fibroblasts) may be caused by a delayed proteolysis of the mutant precursor in the presence of the normal protein, as previously described for a β-D-glucuronidase missense mutation expressed in COS cells. The stability of the L41P precursor may vary in the different tissues as the recognition of the misfolded polypeptide may depend on the cell types. Furthermore, a severe phenotype would be avoided if only 1% of this precursor is processed and active and such a low level would not be detected by our expression study experiments.

X inactivation study was also performed in case 1 and her mother by analysing the methylation status at three polymorphic loci, MAOA, HUMARA, and DXS255. At the DXS255 locus (fig 3B), case 1’s maternal allele is uncut; in her mother and sister, 50% of both alleles are cut. At the DXS255 locus (fig 3A), case 1’s allele 1 is resistant to HhaI digestion, while her allele 2 appears almost completely digested. Fifty percent of both alleles are cut in her mother. Analysis at the MAOA and HUMARA loci confirmed these results. Thus, X inactivation is skewed in case 1 and random in her mother, but this mechanism is not implicated in case 1’s disease.

Case 2 was born to first cousin Tunisian parents. At the age of 3 years 6 months, she had a coarse face, hearing loss, hepatosplenomegaly, severe thoracolumbar kyphosis, limitations of joint mobility, mental retardation, and mitroaortic valvular dysplasia, but no corneal clouding. She had a severe form of the disease and died at the age of 10 years. A unique IDS transcript with a complete deletion of exon 8, resulting in the omission of 38 of the 550 amino acids of the IDS protein, was identified in fibroblasts. The exon 8 skipping was caused by a 3254 bp deletion in genomic DNA, extending from intron 7 (nt 17419, L35485) to intron 8 (nt 20692, L35485) with an insertion of 20 nucleotides (5’-CCACACAGGCATGAGCCATG).

The presence or absence of the IDS polypeptide is indicated by + or −.

Table 2 IDS activities in μmol.h⁻¹.mg⁻¹ in the different cell types transfected by the wild type cDNA (L41L), the mutant cDNA (L41P) or not transfected (NT). The basal level of IDS activity in COS cells and normal fibroblasts was subtracted

<table>
<thead>
<tr>
<th>Activity in μmol.h⁻¹.mg⁻¹</th>
<th>76 kDa</th>
<th>90 kDa</th>
<th>55 kDa/45 kDa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal fib</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L41L</td>
<td>4.00 ± 1.21 (n=3)</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>L41P</td>
<td>1.15 ± 0.38 (n=3)</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>NT</td>
<td>0.23 ± 0.03 (n=3)</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Lß del</td>
<td>4.83 ± 0.12 (n=2)</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>L41P</td>
<td>0.00 (n=2)</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>NT</td>
<td>0.00 (n=2)</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>COS</td>
<td>48.93 ± 21.1 (n=3)</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>L41P</td>
<td>1.85 ± 0.07 (n=3)</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>NT</td>
<td>1.53 ± 0.03 (n=3)</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>
Somatic cell hybrid clones were obtained. Parental origin, and mutation. Four hamster-patient

Nine of the polymorphic markers were informative for case (nt 20274 in intron 8, primers del S and del AS, table 1). Of Chinese hamster ovary (CHO) cells (RJK88 from Cori- check if the patient's active X chromosome carries the cell hybrids with patient fibroblasts were established to able somatic cells (leucocytes, skin fibroblasts), somatic clones were carrying the complex mutation 17419del3254/17418ins20 (no DB5–DB6 PCR product).

Case 2 had a skewed X inactivation and her active X was carrying the severe complex mutation. This deletion appeared de novo on the paternal X chromosome (unaffected father, study of somatic cell hybrids) and case 2 was the only carrier in the family. She was also the only female in this family who had skewed X inactivation. The unbalanced X inactivation was probably identical in almost all her cells as she presented with a severe phenotype.

Our two female patients presented with skewed X inactivation. Plenge et al18 reported a heterozygous C to G mutation at position 6433 in the XIST X inactivation specific transcript) minimal promoter (U50908) on the inactive X chromosome in two unrelated females with familial skewed X chromosome inactivation. They suggested that a substitution in the XIST promoter could play a role in the X inactivation process. The XIST promoter region from our patients was amplified and sequenced. We identified four differences from the published sequences on both chromosomes of our two patients: G to T substitution at 6028 (U50908) and three insertions (311insT, 652insT, and 700insG: M97168). These four sequence differences were also present in all the control X chromosomes tested (30 normal females and 19 normal males). Thus, they were not involved in the process of X inactivation and probably represent sequencing errors in U50908 and M97168. Our patients were both negative for the mutation C6433G described by Plenge et al18 and no specific nucleotide substitution could be identified but there was no familial context of skewed X inactivation in these two cases. These two MPS II affected females illustrate two different mechanisms by which females can be affected by recessive X linked disorders. The skewed X inactivation of the normal X chromosome in a carrier female has been documented in four other cases of MPS II, as in many other X linked diseases. Our patient 1 is the first case of an affected MPS II female with two mutated IDS genes.

This work was supported by grants from Vaincre les Maladies Lysosomales and Fondation pour la Recherche Médicale. We thank Professor J Hopwood (Australia) for providing the IDS cDNA clone and K Timms (USA) for providing a cosmid containing the total IDS gene.

HUMARA, and FMR-1(14) confirmed these results except for the MAOA locus, which was not informative for her mother. As the father does not carry the mutation in available somatic cells (leucocytes, skin fibroblasts), somatic cell hybrids with patient fibroblasts were established to check if the patient's active X chromosome carries the deletion.

Cell fusion of a 6-thioguanine ouabain resistant variant of Chinese hamster ovary (CHO) cells (RJK88 from Coriell Cell Repositories) with patient fibroblasts was performed with polyethylene glycol.15 Selection for hybrids was carried out by maintaining the cultures in Dubelco's HAT-ouabain medium. The HAT-ouabain resistant clones were harvested six weeks later by scraping and expanded for DNA analysis. The RJK88-case 2 somatic cell hybrids were tested for the deletion by genomic PCR primed with DB5 (exon 8, table 1) and DB6 (exon 8, table 1) resulting in a 173 bp fragment. These primers are included in the deletion, so no PCR product would be obtained if only the mutated allele is present. The parental origin of the X chromosome in hamster/human somatic hybrid clones was established by testing 15 microsatellites surrounding the IDS gene (DXS8028, DXS8045, DXS1200, DXS998, DXS8091, DXS1215, DXS1193, DXS8084, DXS8043, DXS8068, DXS8061, DXS8013, DXS8069,16 and DXS111317) and one intragenic SstI polymorphism (nt 20274 in intron 8, primers del S and del AS, table 1). Nine of the polymorphic markers were informative for case 2 and two were selected (DXS1113 and DXS8086) for the analysis of CHO patient somatic cell hybrids (X number, parental origin, and mutation). Four hamster-patient (RJK88-case 2) somatic cell hybrid clones were obtained. Two clones retained only one X chromosome of paternal origin as shown by DXS1113 and DXS8086. These two clones were carrying the complex mutation 17419del3254/17418ins20 (no DB5–DB6 PCR product).

Case 2 had a skewed X inactivation and her active X was carrying the severe complex mutation. This deletion appeared de novo on the paternal X chromosome (unaffected father, study of somatic cell hybrids) and case 2 was the only carrier in the family. She was also the only female in this family who had skewed X inactivation. The unbalanced X inactivation was probably identical in almost all her cells as she presented with a severe phenotype.

Our two female patients presented with skewed X inactivation. Plenge et al18 reported a heterozygous C to G mutation at position 6433 in the XIST (X inactivation specific transcript) minimal promoter (U50908) on the inactive X chromosome in two unrelated females with familial skewed X chromosome inactivation. They suggested that a substitution in the XIST promoter could play a role in the X inactivation process. The XIST promoter region from our patients was amplified and sequenced. We identified four differences from the published sequences on both chromosomes of our two patients: G to T substitution at 6028 (U50908) and three insertions (311insT, 652insT, and 700insG: M97168). These four sequence differences were also present in all the control X chromosomes tested (30 normal females and 19 normal males). Thus, they were not involved in the process of X inactivation and probably represent sequencing errors in U50908 and M97168. Our patients were both negative for the mutation C6433G described by Plenge et al18 and no specific nucleotide substitution could be identified but there was no familial context of skewed X inactivation in these two cases. These two MPS II affected females illustrate two different mechanisms by which females can be affected by recessive X linked disorders. The skewed X inactivation of the normal X chromosome in a carrier female has been documented in four other cases of MPS II, as in many other X linked diseases. Our patient 1 is the first case of an affected MPS II female with two mutated IDS genes. This work was supported by grants from Vaincre les Maladies Lysosomales and Fondation pour la Recherche Médicale. We thank Professor J Hopwood (Australia) for providing the IDS cDNA clone and K Timms (USA) for providing a cosmid containing the total IDS gene.


8 Wu BM, Tomatsu S, Fukuda S, Sukegawa K, Ono T, Sly WS. Overexpression rescues the mutant phenotype of L176F mutation causing

Figure 3 X chromosome inactivation analysis at the DXS255 locus (leucocytes). (A) Case 1 (CS) and her mother (M), (B) Case 2 (SD), her mother (M), father (F), brother (B), and sister (S). Pst I digested genomic DNA (+) hybridised with the probe M27 (exon 8, table 1) and HindIII and probed with IDS cDNA. The 12 kb abnormal fragment is detected in case 2. Figure 4 Southern blotting of case 2's family's genomic DNA digested by HindIII and probed with IDS cDNA. The 12 kb abnormal fragment is present only in case 2 (SD).

www.jmedgenet.com


MPS II in females: molecular basis of two different cases

STÉPHANE CUDRY, ISABELLE TIGAUD, ROSELINE FROISSART, VÉRONIQUE BONNET, IRÈNE MAIRE and DOMINIQUE BOZON

J Med Genet 2000 37: e29
doi: 10.1136/jmg.37.10.e29

Updated information and services can be found at:
http://jmg.bmj.com/content/37/10/e29

These include:

References
This article cites 15 articles, 5 of which you can access for free at:
http://jmg.bmj.com/content/37/10/e29#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Collections
Articles on similar topics can be found in the following collections

- Molecular genetics (1254)
- Immunology (including allergy) (604)
- Connective tissue disease (97)
- Metabolic disorders (329)
- Calcium and bone (307)
- Genetic screening / counselling (886)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/